Dr. Brose on Unique Elements of the Lenvatinib Trial

Marcia Brose, MD, PhD, associate professor of Otorhinolaryngology, Head and Neck Surgery, at the Hospital of the University of Pennsylvania, discusses the SELECT trial.

The phase III SELECT trial, which led to the approval of lenvatinib in February 2015 for patients with radioactive iodine-refractory differentiated thyroid cancer, included a more aggressive patient population than the one used in the trial for sorafenib, a similar agent approved 2 years before. Because of this, these two trials should not be compared head-to-head, says Brose.

The SELECT trial was also unique because it allowed for patients treated with lenvatinib in the first-line setting, says Brose. These patients experienced 3.5 months progression-free survival (PFS) to up to 15.1 months PFS. It is unclear if first or second-line use of lenvatinib is best, says Brose, because there has not been a trial that directly tests this question.

<<<

View more from the 2015 CFS Annual Meeting